LEADER 03006nam  22005295  450 
001 9910298585803321
005 20200702175556.0
010   $a981-10-8806-3
024 7 $a10.1007/978-981-10-8806-3
035   $a(CKB)4100000004244324
035   $a(DE-He213)978-981-10-8806-3
035   $a(MiAaPQ)EBC5379952
035   $a(PPN)227399331
035   $a(EXLCZ)994100000004244324
100   $a20180502d2018      u|         0
101 0 $aeng
135   $aurnn|008mamaa
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aTotal Synthesis of Natural Products with Antimicrobial Activity /$fby Andrew Giltrap
205   $a1st ed. 2018.
210  1$aSingapore :$cSpringer Singapore :$cImprint: Springer,$d2018.
215   $a1 online resource (XXIV, 268 p. 144 illus., 59 illus. in color.) 
225 1 $aSpringer Theses, Recognizing Outstanding Ph.D. Research,$x2190-5053
311   $a981-10-8805-5 
327   $aIntroduction -- Total Synthesis of Teixobactin -- Synthesis of Deshydroxy Skyllamycins A-C -- Total Synthesis of Skyllamycins A-C -- Experimental.
330   $aThis thesis focuses on the development of efficient and scalable total syntheses of natural products that can be used as preferred scaffolds for anti-infective drug discovery. It describes the total synthesis of two classes of antimicrobial non-ribosomal peptides (NRPs) ? teixobactin and the skyllamycins ? with subsequent biological evaluation. The first part describes the first total synthesis of teixobactin by means of a solid-phase peptide synthesis-macrolactamisation approach, yielding a synthetic natural product that can combat a number of clinically relevant Gram-positive bacterial pathogens. The second part describes the first total synthesis of skyllamycins A-C, a family of structurally complex cyclic NRPs, which inhibit the growth of the Pseudomonas aeruginosa biofilms that are responsible for significant mortality among cystic fibrosis patients.
410  0$aSpringer Theses, Recognizing Outstanding Ph.D. Research,$x2190-5053
606   $aMedicinal chemistry
606   $aMedical biochemistry
606   $aDrug resistance
606   $aMedicinal Chemistry$3https://scigraph.springernature.com/ontologies/product-market-codes/C28000
606   $aMedical Biochemistry$3https://scigraph.springernature.com/ontologies/product-market-codes/H35005
606   $aDrug Resistance$3https://scigraph.springernature.com/ontologies/product-market-codes/B16020
615  0$aMedicinal chemistry.
615  0$aMedical biochemistry.
615  0$aDrug resistance.
615 14$aMedicinal Chemistry.
615 24$aMedical Biochemistry.
615 24$aDrug Resistance.
676   $a615.19
700   $aGiltrap$b Andrew$4aut$4http://id.loc.gov/vocabulary/relators/aut$0768751
906   $aBOOK
912   $a9910298585803321
996   $aTotal Synthesis of Natural Products with Antimicrobial Activity$91566586
997   $aUNINA